How has epoprostenol changed the outcome for patients with pulmonary arterial hypertension?

International Journal of Clinical Practice

Volumn 64, Issue SUPPL. 168, 2010, Pages 23-32

  Barst, R ^a  

^a NewYork Presbyterian Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANTIHISTAMINIC AGENT; CALCIUM CHANNEL BLOCKING AGENT; CORTICOSTEROID; PARACETAMOL; PHOSPHODIESTERASE V INHIBITOR; PROSTACYCLIN; TOXIN; UNIPROST; VASODILATOR AGENT;

ASCITES; AUTOIMMUNE DISEASE; BACTEREMIA; CLINICAL TRIAL; CONGENITAL HEART DISEASE; CONNECTIVE TISSUE DISEASE; CONTINUOUS INFUSION; CORONARY STEAL; DIARRHEA; DISEASE ASSOCIATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG HALF LIFE; DRUG INDUCED DISEASE; DRUG INDUCED HEADACHE; DRUG SAFETY; EXERCISE; EXERCISE TOLERANCE; FLUSHING; FOOT PAIN; FUNCTIONAL STATUS; HEMODYNAMIC PARAMETERS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOTENSION; IMPOTENCE; INFECTION; INTERSTITIAL LUNG DISEASE; JAW PAIN; LEG PAIN; LUNG ARTERY PRESSURE; LUNG EDEMA; LUNG HEMORRHAGE; LUNG TRANSPLANTATION; LUNG VASCULAR RESISTANCE; NAUSEA; OXYGENATION; PAIN; PORTAL HYPERTENSION; PRIORITY JOURNAL; PULMONARY HYPERTENSION; QUALITY OF LIFE; REVIEW; SCLERODERMA; SEPTICEMIA; SIDE EFFECT; SURVIVAL; THROMBOCYTOPENIA; THROMBOEMBOLISM; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME; UNEASINESS; VOMITING; WEIGHT REDUCTION;

EID: 78649268352     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2010.02525.x     Document Type: Review

References (14)

1. D'Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension: results from a national prospective registry. Ann Intern Med 1991; 115: 343 - 9.
2. Risk C, Rie M, Peterson M, et al. Thromboxane and prostacyclin (epoprostenol) during exercise in diffuse pulmonary fibrosis. Lancet 1982; 320: 1183 - 5.
3. Rubin LJ, Groves BM, Reeves JT, et al. Prostacyclin-induced acute pulmonary vasodilation in primary pulmonary hypertension. Circulation 1982; 66: 334 - 8.
4. Higenbottam T, Wheeldon D, Wells F, Wallwork J,. Long-term treatement of primary pulmonary hypertension with continuous intravenous epoprostenol (prostacyclin). Lancet 1984; 8385: 1046 - 49.
5. Rubin LJ, Mendoza J, Jood M, et al. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (Epoprostenol): results of a randomized trial. Ann Intern Med 1990; 112: 485 - 91.
6. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (Prostacyclin) with conventional therapy for primary pulmonary hypertension: the primary pulmonary hypertension study group. New Engl J Med 1996; 334: 296 - 302.
7. Badesch DB, Tapson VF, McGoon MD, et al. Continuous intravenous epoprostenol for pulmonary hypertension secondary to the scleroderma spectrum of disease. A randomized controlled trial. Ann Int Med 2000; 132: 425 - 34.
8. McLaughlin VV, Shillington A, Rich S,. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation 2002; 106: 1477 - 82.
9. Sitbon O, Humbert M, Nunes H, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 2002; 40: 780 - 8.
10. Barst RJ, Maislin G, Fishman AP,. Vasodilator therapy for primary pulmonary hypertension in children. Circulation 1999; 99: 1197 - 208.
11. Yung D, Widlitz AC, Rosenzweig EB, et al. Outcomes in children with idiopathic pulmonary arterial hypertension. Circulation 2004; 110: 660 - 5.
12. McLaughlin V, Genthner DE, Panella MM, Rich S,. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. N Engl J Med 1998; 338: 273 - 7.
13. Oudiz RJ, Widlitz A, Beckmann XJ, et al. Micrococcus-associated central venous catheter infection in patients with pulmonary arterial hypertension. Chest 2004; 126: 90 - 4.
14. Melnick L, Barst RJ, Rowan CA, et al. Transition from IV epoprostenol to oral/inhaled targeted pulmonary arterial hypertension therapy in pediatric idiopathic pulmonary arterial hypertension. Circulation 2008; 118: S877.